S&P has cut AstraZeneca's (AZN +0.1%) credit outlook to negative as the company's plan to...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

S&P has cut AstraZeneca's (AZN +0.1%) credit outlook to negative as the company's plan to arrest falling revenues failed to impress. According to S&P, the loss of patent protection on key products will erode the company's top line by 9% in 2013, which could in turn cause AZN's funds from operations to net debt ratio to fall below the minimum level for AA-.